Reference - LUMIGAN

Phase 3Small molecule

AAmneal Pharmaceuticals, LLC

Reference - LUMIGAN is one of 41 small molecule programs targeting Ocular Hypertension. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ocular HypertensionActive, not recruiting

Open-Angle GlaucomaActive, not recruiting

Ocular HypertensionPhase 3

Active, not recruiting

Open-Angle GlaucomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

187 competitors in Ocular Hypertension

#DrugCompanyPhaseTrials

Alphagan

Novartis

Phase 3

1 2

Timolol Maleate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

9 3

Comparator: Pbo

Merck & Co.

Phase 3

2 4

Ocupress

AbbVie

Phase 3

1 5

LUMIGAN

AbbVie

Phase 3

2 6

Krytantek

AbbVie

Phase 3

2 7

Bimatoprost/timolol

AbbVie

Phase 3

4 8

Reference - LUMIGAN

AAmneal Pharmaceuticals, LLC

Phase 3

1 9

Duotrav

AAlcon Research

Phase 3

1 10

Combigan

EEMS

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ocular Hypertension1 trial

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

Recruiting·AAmneal Pharmaceuticals, LLC·Phase 3·NCT05401357·168 enrolled

Open-Angle Glaucoma1 trial

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma

Completed·MMankind Pharma Limited·Phase 3·NCT04890106·310 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Reference - LUMIGAN. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Reference - LUMIGAN compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Reference - LUMIGAN. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amneal Pharmaceuticals, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAmneal Pharmaceuticals, LLC

Reference - LUMIGAN

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ocular Hypertension1 trial

Open-Angle Glaucoma1 trial

References

Drug Info

Quick Facts

Related News